Trials / Terminated
TerminatedNCT06025110
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
A 12-month, Randomized, Single-blind, Placebo-controlled Exposure-response Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients (STRIDE)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- ITB-Med LLC · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TCD601 | Investigational Product |
| OTHER | Placebo | Comparator |
Timeline
- Start date
- 2023-01-23
- Primary completion
- 2025-07-24
- Completion
- 2025-07-24
- First posted
- 2023-09-06
- Last updated
- 2025-08-14
Locations
26 sites across 5 countries: Belgium, Italy, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT06025110. Inclusion in this directory is not an endorsement.